doctor and rep

Changing the way we work with healthcare professionals

We are leading the industry in changing the way we work with doctors and other healthcare professionals. Our Chief Medical Officer, Murray Stewart, explains how these changes put patients’ interests at the heart of every decision we take.

Our new practices are intended to provide doctors with high quality up-to-date information about our medicines to help them make the best treatment choices for their patients.

As a pharmaceutical company we work with doctors and healthcare professionals (HCPs) in a number of ways. We share information about our medicines to help HCPs make the right prescribing decisions for patients. Doctors have spoken on our behalf about our medicines to their peers, and been paid a fee for that, and we have supported their attendance at educational meetings. They also share their scientific and medical expertise, and their experience of caring for patients with us as advisors.  

Murray Stewart, Chief medical officer discussing healthcare professionals
Murray Stewart, Chief Medical Officer

We believe the relationship between pharmaceutical companies and HCPs relationship is fundamental to the progress of medical science and to help meet patient and public health needs.

We also recognise a growing concern that the way the industry currently provides information and education to HCPs may be perceived to inappropriately influence prescribing decisions. This is why we have committed to changing the way we work with doctors and HCPs.

The first of these changes is a new way to remunerate our sales professionals. From January 2015, none of our sales professionals around the world have individual sales targets. Instead, they are rewarded on their technical knowledge and the quality of the service their deliver to HCPs.

Secondly, we believe that we continue to have an important role in supporting the continued education of HCPs with information on disease, diagnosis and treatment, supplementing the education provided by governments and their employers. But, we will approach this differently to remove any perception of inappropriately influencing prescribing decisions.